gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ARWRHealthcarePharmaceuticals

Arrowhead Research Corporation (ARWR)

$61.65+3.56%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$61.65▲ 62.88% in range
Nov 4, 2025Low $37.85 · High $89.59Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Arrowhead Research closed at $61.65 on Nov 4, up 3.56%, 31.2% below its 52-week closing high. Volume of 1.6M shares was 0.96× its 20-day average (close to normal).

Split-adjusted performance: +0.2% over one month, -22.1% over six months, +55.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $75.25M, up 171.0% from a year earlier, with a net margin of -258.2%.

Short interest was 11.0M shares at the Oct 15 settlement, up 1.8% from the prior report (8.1% of float, 5.4 days to cover).

Market cap$8.71B141.3M shares
Revenue · quarter$75.3M+171.0% YoY
Diluted EPS$-1.36—
P/E · TTM—P/S 13.0×
Net margin-258.2%Gross 100.0%
Dividend yieldNone
52-week range37.85 – 89.59−31.2% from high
Volume1.6M0.96× 20-day avg
Volatility · 60d45.8%Annualised
Short % of float8.1%5.4 days to cover
Net cash$737.9MCash $1.60B
Next earnings—Not scheduled
Split-adjusted performance
1W +2.4%1M +0.2%3M −28.2%6M −22.1%YTD −7.1%1Y +55.6%3Y +165.5%5Y −4.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum55
Revenue growth88
Net margin33
Value (low P/E)—
Size94

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short11.0M+1.8% vs prior
Days to cover5.4Settled Oct 15
% of float8.1%
Short vol. 10d52.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ARWRArrowhead Research$61.65+3.56%−22.1%+171.0%−258.2%—$8.71B
CYTKCytokinetics$63.60+2.07%−15.0%−57.1%−694.4%—$8.84BCompare
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56BCompare
MDGLMadrigal Pharmaceuticals$400.43+1.04%−25.8%+50.1%12.9%—$9.25BCompare
SYRESpyre Therapeutics$99.04−0.23%+35.7%———$9.26BCompare
PTGXProtagonist Therapeutics$143.37+2.23%+37.9%+3749.2%76.3%111.9$9.28BCompare
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare
ALKSAlkermes$45.89+0.44%+29.9%+21.8%3.4%—$7.70BCompare

News about Arrowhead Research

All news →

No recent articles focused on Arrowhead Research. 5 articles mention it in passing.

Quick answers

What does Arrowhead Research do?
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction.
What is ARWR's market cap?
$8.71B, based on the Nov 4 close of $61.65.
Does Arrowhead Research pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ARWR is sold short?
11.0M shares, 8.1% of float, as of Oct 15, 2026.
What sector is ARWR in?
Healthcare, in the Pharmaceuticals industry.

About Arrowhead Research

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

HQ: Pasadena, CA711 employeesListed Feb 1, 1995arrowheadpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology